| Mortality | Patients n | Biomarker | |||
| CRP mg·L−1 | WBCs ×103 cells·μL−1 | PCT ng·mL−1 | MR-proADM nmol·L−1 | ||
| 30-day | 224 | ||||
| Survivors | 211 | 156.4 (89.0–286.9) | 11.85 (8.4–16.83) | 0.41 (0.09–3.50) | 0.856 (0.592–1.911) |
| Deaths | 13 | 238.3 (123.4–332.5) | 14.7 (6.5–17.8) | 1.174 (0.477–6.69) | 2.341 (1.188–4.226) |
| p-value | 0.262 | 0.914 | 0.123 | <0.0001 | |
| 90-day | 220 | ||||
| Survivors | 200 | 155.8 (89.1–287.3) | 11.9 (8.4–16.6) | 0.376 (0.09–3.53) | 0.839 (0.578–1.158) |
| Deaths | 20 | 228.9 (77.6–283.0) | 10.5 (8.0–17.9) | 1.024 (0.21–3.18) | 1.731 (1.072–2.515) |
| p-value | 0.535 | 0.915 | 0.151 | <0.0001 | |
| 180-day | 218 | ||||
| Survivors | 192 | 155.6 (89.8–287.2) | 11.75 (8.4–16.4) | 0.373 (0.085–3.63) | 0.838 (0.578–1.139) |
| Deaths | 26 | 228.9 (91.1–287.4) | 14.7 (8.2–18.7) | 1.004 (0.13–2.94) | 1.476 (1.056–2.43) |
| p-value | 0.391 | 0.519 | 0.158 | <0.0001 | |
| 1-yr | 150 | ||||
| Survivors | 132 | 144.7 (71.7–253.0) | 11.65 (8.3–16.4) | 0.255 (0.076–4.41) | 0.772 (0.50–1.03) |
| Deaths | 18 | 251.9 (181.0–323.3) | 16.1 (10.5–21.9) | 1.134 (0.429–6.68) | 1.238 (1.044–2.471) |
| p-value | 0.030 | 0.060 | 0.069 | <0.0001 | |
Data are presented as median (interquartile range), unless otherwise stated. CRP: C-reactive protein; WBC: white blood cell; PCT: procalcitonin; MR: midregional; proADM: proadrenomedullin. Bonferroni correction was applied (p≤0.003125). Bold indicates statistically significant p-values.